Issue link: https://beckershealthcare.uberflip.com/i/1480010
9 INFECTION CONTROL Image Credit: Adobe Stock a mortality of 30 percent. Again, because of a failure to intervene soon enough," Dr. Cohen added. e study also showed that providers were willing to trust AI and ma- chine learning in their clinical practice. In interviews, clinicians re- vealed they perceive themselves as partnering with the technology even without a deep understanding of machine learning. "is tool makes every clinician more efficient and can let you man- age more patients because there's less work to do," said Lee Sacks, MD, founding CEO of Advocate Physician Partners and former system chief medical officer of Downers Grove, Ill., and Milwaukee-based Advocate Aurora Health. "So I think, going forward … [staff] are going to choose to work in organizations that have a tool like this because it makes them more effective." Dr. Saria added that this system may show that a similar approach could generate results in other clinical areas. "It's much easier to take a platform that shows really high-quality results in a tough use case like sepsis and now start to generate results in other clinical areas," Dr. Saria said. n 2 infectious disease experts among Fast Company's 56 most creative people in business By Mackenzie Bean T wo infectious disease experts from Houston-based Texas Children's Hospital were recognized among Fast Company's 14th annual list of the most creative people in business. The list, published Aug. 9, celebrates 56 leaders who've accomplished groundbreaking feats in their industries. Fast Company recognized Maria Elena Bottazzi, PhD, and Peter Hotez, MD, PhD, co-directors of the Texas Children's Hospital Center for Vaccine Development at Baylor College of Medicine, for creating the first open-source COVID-19 vaccine. The vaccine, named Corbevax, is low cost and easy to store, making it an ideal candidate for low- and middle- income countries. Thirty million doses of the vaccine have already been administered in India under an emergency use approval, according to Fast Company. "We appreciate the recognition of our efforts to begin the long road to 'decolonize' the vaccine development ecosystem and make it more equitable," Dr. Bottazzi said in a news release. "We hope that Corbevax becomes one of a pipeline of new vaccines developed against many neglected and emerging infections that adversely affect global public health." n